Edgemont Capital Partners Completes Sale of Compass Research to Bioclinica
Edgemont Capital acted as exclusive financial advisor to Compass Research in its sale to Bioclinica
NEW YORK & ORLANDO, Fla.–(BUSINESS WIRE)–Edgemont Capital Partners, a leading independent healthcare investment banking firm, today announced that it served as exclusive financial advisor to Compass Research, LLC in the company’s sale to Bioclinica announced on July 25, 2016.
Compass Research, a leading provider of neuroscience drug development clinical research services, focuses on conducting Phase I-IV clinical trials in central nervous system (CNS) disorders, as well as other therapeutic areas. The Compass Research transaction team was led by David Blume, Managing Director and Head of Edgemont’s Pharmaceutical Services Group, Reid Petersen, an Associate with Edgemont, and Jay Moon, an Analyst with the firm. The sale of Compass Research is the 13th clinical research site company transaction closed by Edgemont, and the 12th transaction for a CNS focused outsourced pharmaceutical services company.
“The highly fragmented clinical research site services market is consolidating rapidly. Leading companies in the industry, particularly those with strong clinical and therapeutic expertise such as Compass Research, are in increasingly high demand by a growing number of strategic and financial buyers. These acquirers are seeking to capitalize on benefits of scale for site services given evolving clinical trials business dynamics and in order to address the acute challenges of subject recruitment. As a result, we expect industry consolidation to accelerate,” said Blume.
Founded in 2006, Compass Research conducts early and late stage clinical research studies for global and mid-sized pharmaceutical and biotech sponsors, as well as leading Contract Research Organizations (CROs), in its state-of-the-art research facilities and clinical pharmacology units located in Orlando, the Villages and Melbourne, all in Florida. The Company is a leading neuroscience research site services company, and also performs studies in a broad range of other indications.
“We selected Edgemont as our advisor based on their unparalleled M&A expertise in the clinical research services industry and extensive experience advising companies focused on CNS drug development services. Their industry knowledge and transaction expertise were an ideal fit with our strategic needs. We appreciate Edgemont’s commitment to our Company in the sale process. They proved to be a trusted and immensely valuable advisor. Their efforts resulted in a highly successful transaction with an exceptional partner for our Company in Bioclinica,” said Sean Stanton, CEO of Compass Research.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Clinverse Financial Lifecycle Solutions; Safety and Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment-retention services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. Learn more at www.bioclinica.com.
About Edgemont Capital Partners
Edgemont Capital Partners is a leading independent investment banking firm focused on the merger and acquisitions advisory and financing needs of healthcare companies. Edgemont’s deep healthcare industry knowledge and extensive transaction expertise supports the firm’s unsurpassed ability to address healthcare companies’ strategic advisory (M&A) and financing needs with great success. Edgemont provides sell-side and acquisition advisory, restructuring advisory, board advisory and private placement services.
For more information on Edgemont Capital Partners Pharmaceutical Services expertise contact David Blume at +1 (212) 867-8937 and see www.edgemontcapital.com.
Investment banking services are provided by Edgemont Capital Partners, LP, a registered broker-dealer and member of FINRA and SIPC.
Edgemont Capital Partners
David Blume, +1 212-867-8937